JOIN OUR EUROPE 2018 STRATEGY MEETING
6th March 2018 | Radisson Blu, Zurich Airport, Switzerland
OUR UNIQUE FORMAT
The Medicinal Chemistry Roundtable Discussions Strategy Meeting are for qualified end-users.These include Senior Executives of Early Drug Discovery (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Chemistry, Immunology Chemistry, Chemistry Technologies, Medicinal and Innovative Chemistry, Drug Discovery & DMPK, Chemical and Molecular Therapeutics, Chemical Development, Biochemistry & Molecular Pharmacology, Computational and Structural Chemistry, Biochemistry.
Those who do not qualify for VIP passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Magnus WalterChief Scientific Officer, Head of Chemistry
Eli Lilly and Company
Sergio LociuroChief Scientific Officer
Dr Joël RichardSenior Vice President, Peptides
Bayard R HuckVice President, Global Head of Medicinal Chemistry
Thorsten ThormannVice President, Research
Nicholas TerrettAssociate Vice President and European Chemistry Lead
Merck Sharp & Dohme Research GmbH
Tobias GabrielGlobal Head, External Science & Drug Discovery, Global Discovery Chemistry
Stephan ZahnDirector, Medicinal Chemistry
Klaus UrbahnsSenior Vice President, Discovery Technologies
Darryl McConnellVice President, Discovery Research Site Head, Austria
Jean KimSenior Vice President, Chemistry
WHAT TO EXPECT
Interactive Roundtable Discussions
Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.
Director level one-to-one meetings
We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.
Tailor-fit and Personalized Agenda
Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.
Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.
Thank you for reaching Proventa International
***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.
Our unique strategy meeting platform ensures that delegates can network with peers and benchmark their challenges whilst meeting a select number of supplier organizations that are currently at the forefront of innovation. This in turns helps them to save time and money associated in sourcing the best suppliers to procure solutions in an environment, which is 100% conducive to doing business.
If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies, or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!
WHAT PEOPLE SAYS
Return on Investment, Medicinal Chemistry Strategy Meeting Europe 2016
Chief Information Officer
Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative
Ivan John Clement
Data Scientist - R&D
Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.
Manager Quality Assurance
The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.
Founder & President
The kind of interaction is very interactive
Director & Professor
Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.
RADISSON BLU HOTEL,
ZURICH AIRPORT, SWITZERLAND
Rondellstrasse, 8058 Kloten, Switzerland
+41 44 800 40 40
OUR MEDIA PARTNERS
Senior Vice President, Discovery Technologies
Klaus Urbahns has more than 20 years of experience in the biopharmaceutical industry. He is Senior Vice President, Head of the Discovery Technology Platform at MerckSerono with laboratories in the US, Israel and Germany. His team’s role is to generate small molecule drug candidates and therapeutic proteins. Prior to joining Merck, Klaus served at AstraZeneca in the UK and Sweden. He started his professional career at Bayer, holding positions in Germany and Japan. Klaus is member of the advisory board of the Lead Discovery Center (LDC) and the Medicines for Malaria Venture (MMV). Klaus studied chemistry at the universities of Kiel, Freiburg and Frankfurt.
Vice President, Discovery Research Site Head, Austria
Darryl McConnell is currently Research Site Head and Head of Medicinal Chemistry at Boehringer-Ingelheim Regional Centre Vienna, Austria where the main research focus is oncology. Darryl commenced his career with Boehringer-Ingelheim in 2002 as a Research Laboratory Head and is in his current role since 2015.
Prior to this Darryl has worked for Intervet in Vienna from 2001, for Biota Holdings Ltd in Melbourne, Australia from 1999 in the area of respiratory viruses and Chiron Technologies in Melbourne from 1997.
Darryl McConnell received his Bachelor of Science with First Class Honours in 1991 with Professor John Elix at the Australian National University in Canberra. He performed his PhD at the University of New South Wales in Sydney with Professor David Black for which he was awarded the Cornforth Medal for the best chemistry PhD thesis in Australia for that year. Following this he performed a 2 year Postdoctoral study at the University of Sydney with Professor Leslie Field in organometallic chemistry.
Darryl’s interest lie in the areas of cancer cell directed and immune cell directed therapies for cancer as well as protein crystallography and protein NMR, fragment based and structure based drug discovery, drug discovery software , agile methods in drug discovery and natural product inspired medicinal chemistry.
Senior Vice President, Chemistry
Jean Kim is a Senior V.P. of Chemistry at Kadmon where she currently leads the discovery of small molecule therapeutic agents for Oncology, Autoimmunity, and Anti-infective diseases. She directed numerous research programs at Merck and Wyeth Laboratories and has worked in the field of Medicinal Chemistry Research for over 20-years, towards finding therapies for Metabolic Syndrome and Diabetes, and Neurological disorders. Jean is a co-inventor of Nemonoxacin, an antibiotic marketed for the treatment of community-acquired pneumonia (CAP). Jean received her Ph.D. in organic chemistry from University of Illinois, at Champaign-Urbana, and completed post-doctoral research in University of Basel, Switzerland after receiving her B.S. in chemistry from Cornell University.
Chief Scientific Officer, Head of Chemistry, Eli Lilly and Company
JMagnus Walter received a Master’s degree in Chemistry from the University of Bonn in Germany and a doctorate from the University of Oxford for his work on resistance against ß-lactam antibiotics. After starting his industrial career at Zeneca in 1998 as chemistry team leader he has worked for Eli Lilly since 2001 based at Lilly’s Erl Wood Research Centre in the UK. In 2012 he become Head of Department at Lilly’s UK Research Centre leading a group of approximately one hundred chemists focused on drug discovery in the areas of neurodegeneration, pain and endocrinology. Since 2014 he is Chief Scientific Officer in Medicinal Chemistry with global portfolio responsibility of Lilly’s chemistry research in the area of Neurodegeneration.
Chief Scientific Officer, Bioversys AG
Sergio received his Laurea degree in Chemistry at the University of Rome in 1981. After a two-year postdoctoral fellowship at the Italian CNR, he moved to UNB, Canada, where he received his Ph.D in 1987. In his almost 30 years experience in major pharmaceutical companies and SMEs, Sergio has held positions such as Director of Medicinal Chemistry and International Project Leader in GSK, Head of PEM in Polyphor, Head of Research in Arpida and CSO to C10-Pharma and Adenium. Founder of THOT consulting, a consulting firm in DD, he is currently CSO to BioVersys. His experience spans from early drug discovery to the conduction of Phase I studies.
Dr Joël Richard
Senior Vice President, Peptides, Ipsen
Dr Joël Richard is presently leading all the Pharmaceutical Development activities of Peptides & Small Molecules for the Ipsen Company. Dr Richard has got his PhD in Materials Science/Colloids & Interface Science from University of Paris VI. He has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several global senior leadership positions in various Biotech and Pharma companies, such as Ipsen, Merck Serono, Serono and Ethypharm. Dr Richard has focused his research activity on innovative drug delivery especially for injectable protein and peptide formulations. Dr Richard has published 68 peer-reviewed scientific papers, 8 book chapters and 2 editorials in various fields. He is the author of more than 120 international communications and 53 patent families.
Bayard R. Huck
Vice President, Global Head of Medicinal Chemistry, Merck
Bayard Huck is currently the Global Head of Medicinal Chemistry at Merck Biopharma (subsidiary of Merck KGaA). Bayard received his Ph.D. in Organic Chemistry from the University of Wisconsin – Madison. His medicinal chemistry experience ranges from driving multiple small molecule programs from concept to clinic, to leading multiple programs to clinical proof of concept. Currently, as Global Head of Medicinal Chemistry, Bayard oversees the medicinal chemistry efforts at Merck Biopharma in support of Immunology, Immuno-Oncology, and Oncology therapeutic areas.
Vice President, Research, LEO Pharma
Thorsten Thormann is Vice President of Research in LEO Pharma A/S and has over 15 years of experience within biomedicine and drug research. Prior to being Vice President of Research, Thorsten has held a number of leadership positions within LEO Pharma aiming to build translational drug discovery platforms in dermatology as well as refocusing the early formulation and CMC to build a platform for product improvements based on usability and patient driven innovation. Thorsten Thormann has a MSc in Chemistry from the University of Roskilde and a PhD in Protein Biology from the University of Copenhagen.
Associate Vice President and European Chemistry Lead, Merck Sharp & Dohme Research GmbH
Nick Terrett is Associate Vice President and European Chemistry Lead for Merck Sharp & Dohme Research GmbH in Lucerne, Switzerland. Previously he was CSO at Ensemble Therapeutics, a biotech company based in Cambridge, Massachusetts, with a focus on the discovery of novel macrocycles with affinity for significant oncology targets. Before Ensemble, much of Nick’s career was at Pfizer both in the UK and US where, among other activities, he was lead chemist and inventor for the program that discovered sildenafil (Viagra™, Revatio™). Nick has an MA and PhD in organic chemistry from the University of Cambridge.
Global Head, External Science & Drug Discovery, Global Discovery Chemistry, Novartis
Tobias Gabriel is the Global Head of External Drug Discovery at Global Discovery Chemistry, Novartis Institutes for BioMedical Research. Prior to his current role Tobias was Head of Oncology Chemistry, Basel and Shanghai. Tobias joined Novartis seven years ago from Roche where he held positions of increasing responsibility in Medicinal Chemistry in Palo Alto and as Director of Research Strategy in Basel. Tobias studied Chemistry in Berlin and completed his Ph.D. in Organic Chemistry in Munich, followed by postdoctoral studies in nanotechnology at the Hebrew University of Jerusalem.
Director, Medicinal Chemistry, Boehringer-Ingelheim
Born in Wilhelmshaven, Germany. Studies of Chemistry at the University of Marburg and Edinburgh from 1992 to 1997. Diploma with Prof. Dr. R. W. Hoffmann in 1997. Received PhD in 2001 under the supervision of Prof. Dr. B. Breit working in Marburg and Heidelberg on Stereoselective Hydroformylation for the construction of Stereotriads in Polyketides.
In 2002 joined Boehringer Ingelheim in Vienna to build up the MedChem Facilities for Oncology research. Experience in drug discovery from early stage to clinical candidates. In 2013 appointed Director at Boehringer Ingelheim in Vienna taking responsibility for drug discovery strategy, MedChem and organic synthesis.